

Studio di modelli farmacoforici mediante l'uso del linguaggio di programmazione *Python*. Applicazione a serie di inibitori della chinasi PKC Theta

FACOLTÀ DI FARMACIA E MEDICINA
CORSO DI LAUREA IN BIOTECNOLOGIE FARMACEUTICHE




SAPIENZA
UNIVERSITÀ DI ROMA

**Tesi Sperimentale
in
Chimica Farmaceutica (CHIM08)**


CANDIDATO:
Stefano Masiello (Matr. 1469704)

RELATORE:
Prof. Rino Ragno

ANNO ACCADEMICO
2019/2020



SCOPO DEL LAVORO




Rome Center for Molecular Design

Generazione di
modelli
farmacoforici
mediante RDKit e
LigandScout

Confronto dei
risultati ottenuti
mediante i due
metodi

Generazione di
modelli 3-D QSAR
attraverso la
piattaforma
www.3d-qsar.com



FARMACOFORO




Figura geometrica virtuale ai cui vertici sono posizionate diverse caratteristiche farmacoforiche, legate mediante regole geometriche.


PRINCIPALI CARATTERISTICHE FARMACOFORICHE




**Centroide
Idrofobico**



**Area Ionizzabile
Negativa**



**Accettore
Legame-H**




**Anello
Aromatico**



**Area Ionizzabile
Positiva**



**Donatore
Legame-H**



FARMACOFORO






Figura geometrica virtuale ai cui vertici sono posizionate diverse caratteristiche farmacoforiche, legate mediante regole geometriche.


APPROCCI DI MODELING FARMACOFORICO

LIGAND-BASED PHARMACOPHORE MODELING




STRUCTURE-BASED PHARMACOPHORE MODELING





PROCEDIMENTO



Rome Center for Molecular Design

1

• Creazione di un dataset di molecole

2


• Analisi conformazionale

3

• Allineamento molecolare



4

• Generazione farmacoforo





1. CREAZIONE DATASET


ID MOLECOLA	FORMULA SMILES
A_01	<chem>C1CN(CC[NH2+](1)c1cccc(n1)-c1n[nH]c2ncccc12</chem>
A_18	<chem>CC(C)[C@@](C)(O)[C@@H]1CN(CC[NH2+](1)c1ccc(Cl)c(n1)-c1n[nH]c2ncccc12</chem>
A_20	<chem>CC(C)[C@@](C)(O)[C@@H]1CN(CC[NH2+](1)c1nc(-c2n[nH]c3ncccc23)c(F)cc1O</chem>




A_01




A_18



A_20



2. ANALISI CONFORMAZIONALE



ID MOLECOLA

FORMULA SMILES

A_01



C1CN(CC[NH2+])c1cccc(n1)-c1n[nH]c2cccc12

A_18


CC(C)[C@@](C)(O)[C@@H]1CN(CC[NH2+])c1ccc(Cl)c(n1)-c1n[nH]c2cccc12

A_20

CC(C)[C@@](C)(O)[C@@H]1CN(CC[NH2+])c1nc(-c2n[nH]c3cccc23)c(F)cc1O




A_20




1000 conformazioni

24/01/2019



6




3. ALLINEAMENTO MOLECOLARE




Molecola di riferimento (A_24)




A_20



1000 conformazioni



4. GENERAZIONE FARMACOFORO



Rome Center for Molecular Design

Estrazione delle
caratteristiche
farmacoforiche



Clusterizzazione
delle caratteristiche
farmacoforiche



Generazione del
modello
farmacoforico finale

INTERAZIONI IDROFOBICHE (**HB**)

INTERAZIONI AROMATICHE (**ARO**)

ACCETTORE / DONATORE LEGAME-H (**HBA / HBD**)

AREA IONIZZABILE POSITIVA / NEGATIVA (**POS / NEG**)

K-Means

N° CLUSTER PER TIPOLOGIA DI CARATTERISTICA
SPAZIO MOLECOLARE DELLE CARATTERISTICHE

4. GENERAZIONE FARMACOFORO

Rome Center for Molecular Design

Estrazione delle
caratteristiche
farmacoforiche



Clusterizzazione
delle caratteristiche
farmacoforiche




Generazione del
modello
farmacoforico finale



File .pdb

```
FINAL MODEL
ATOM      0 HBD  HBD      1    -1.985    1.510   -0.733
ATOM      1 HBD  HBD      1     5.788   -1.065    1.572
ATOM      2 HBD  HBD      1     6.621   -1.265    0.535
ATOM      3 HBD  HBD      1     6.610   -1.487   -1.861
ATOM      4 HBA  HBA      1     2.318   -0.155    1.139
ATOM      5 HBA  HBA      1     5.788   -1.065    1.572
ATOM      6 HBA  HBA      1     6.610   -1.487   -1.861
ATOM      7 HB   HB       1     2.128   -0.766    3.837
ATOM      8 HB   HB       1     4.371   -1.286   -2.773
ATOM      9 HB   HB       1     3.809   -1.096   -1.510
ATOM     10 HB   HB       1     4.670   -1.100   -0.410
ATOM     11 ARO  ARO      1     5.533   -1.137    0.407
ATOM     12 ARO  ARO      1     2.223   -0.458    2.482
ATOM     13 ARO  ARO      1     5.201   -1.289   -1.685
ATOM     14 POS  POS      1    -1.985    1.510   -0.733
ENDMDL
END
```

4. GENERAZIONE FARMACOFORO




- **INTERAZIONI IDROFOBICHE - HB (GIALLO)**
- **INTERAZIONI AROMATICHE - ARO (VIOLETTO)**
- **ACCETTORE LEGAME-H - HBA (ROSSO)**
- **DONATORE LEGAME-H - HBD (VERDE)**
- **AREA IONIZZABILE POSITIVA - POS (BLU)**

**Generazione del
modello
farmacoforico finale**




File .pdb


```
FINAL MODEL
ATOM      0 HBD  HBD      1      -1.985   1.510  -0.733
ATOM      1 HBD  HBD      1       5.788  -1.065   1.572
ATOM      2 HBD  HBD      1       6.621  -1.265   0.535
ATOM      3 HBD  HBD      1       6.610  -1.487  -1.861
ATOM      4 HBA  HBA      1       2.318  -0.155   1.139
ATOM      5 HBA  HBA      1       5.788  -1.065   1.572
ATOM      6 HBA  HBA      1       6.610  -1.487  -1.861
ATOM      7 HB   HB       1       2.128  -0.766   3.837
ATOM      8 HB   HB       1       4.371  -1.286  -2.773
ATOM      9 HB   HB       1       3.809  -1.096  -1.510
ATOM     10 HB   HB       1       4.670  -1.100  -0.410
ATOM     11 ARO  ARO      1       5.533  -1.137   0.407
ATOM     12 ARO  ARO      1       2.223  -0.458   2.482
ATOM     13 ARO  ARO      1       5.201  -1.289  -1.685
ATOM     14 POS  POS      1      -1.985   1.510  -0.733
ENDMDL
END
```



APPLICAZIONE: PKC- θ




Catalizza le reazioni di fosforilazione mediando il trasferimento del fosfato gamma di una molecola di ATP sui gruppi idrossilici di serina, treonina o tirosina.




- **FAMIGLIA:** PROTEIN CHINASI C
- **SOTTOFAMIGLIA:** PKC “NUOVE”
- **ISOFORMA:** THETA θ
- **PRINCIPALE LOCALIZZAZIONE:** CELLULE EMATOPOIETICHE

CODICE PDB: 1xjd




ALLINEAMENTI RDKit




Rome Center for Molecular Design


DATASET A




DATASET C




DATASET B




DATASET UNICO





RDKit vs LIGANDSCOUT





RDKit

15 CARATTERISTICHE

DATASET A

LigandScout (LS)

14 CARATTERISTICHE



4

INTERAZIONI IDROFOBICHE (GIALLO)

4

3

INTERAZIONI AROMATICHE (VIOLETTO)

3

1

AREA IONIZZABILE POSITIVA (BLU)

1

3

ACCETTORE LEGAME-H (ROSSO)

4


4

DONATORE LEGAME-H (VERDE)


2

24/01/2019

12



RDKit vs LIGANDSCOUT





RDKit

15 CARATTERISTICHE

DATASET A

LigandScout (LS)

14 CARATTERISTICHE



4

INTERAZIONI IDROFOBICHE (GIALLO)

4

3

INTERAZIONI AROMATICHE (VIOLETTO)

3

1

AREA IONIZZABILE POSITIVA (BLU)

1

3

ACCETTORE LEGAME-H (ROSSO)

4


4

DONATORE LEGAME-H (VERDE)


2

24/01/2019

12




ALLINEAMENTI LS




Rome Center for Molecular Design


DATASET A




DATASET C




DATASET B




DATASET UNICO





RDKit vs LIGANDSCOUT





RDKit

13 CARATTERISTICHE

DATASET A

LigandScout (LS)

13 CARATTERISTICHE



3

INTERAZIONI IDROFOBICHE (GIALLO)

3

3

INTERAZIONI AROMATICHE (VIOLETTO)

3

1

AREA IONIZZABILE POSITIVA (BLU)

1

3

ACCETTORE LEGAME-H (ROSSO)

4


3

DONATORE LEGAME-H (VERDE)


2

24/01/2019

14



RDKit vs LIGANDSCOUT





RDKit

13 CARATTERISTICHE

DATASET A

LigandScout (LS)

13 CARATTERISTICHE



3

INTERAZIONI IDROFOBICHE (**GIALLO**)

3

3

INTERAZIONI AROMATICHE (**VIOLETTO**)

3

1

AREA IONIZZABILE POSITIVA (**BLU**)

1

3

ACCETTORE LEGAME-H (**ROSSO**)

4


3

DONATORE LEGAME-H (**VERDE**)


2

24/01/2019

14




MODELLI 3-D QSAR




Dataset	ID_Model	Probe Atom	q ² STE	q ² ELE	q ² BOTH	ONPC	Grid Spacing	Grid Extension	CutOff	Min. Sigma	CV Type	r ²	SDEC	SDEP
RDKit_A	98	F	0.567	0.445	0.642	3	2.0	10	30.0	1.00	LOO	0.929	0.281	0.630
LS_A	110	S.O	0.415	0.291	0.525	8	1.7	5	20.0	1.60	LOO	0.998	0.041	0.725
RDKit_B	101	Ca	0.868	0.632	0.872	2	2.5	5	35.0	1.15	LOO	0.909	0.416	0.495
LS_B	117	Al	0.869	0.554	0.872	3	1.2	2	20.0	1.95	LOO	0.941	0.336	0.502
RDKit_C	123	K	0.696	0.454	0.674	8	1.0	10	20.0	5.00	LSO	0.948	0.213	0.531
LS_C	123	H.P	0.637	0.385	0.603	7	1.9	5	20.0	4.00	LSO	0.947	0.214	0.586
RDKit_UNICO	122	H.spc	0.701	0.475	0.698	8	1.0	4	35.0	3.00	LSO	0.970	0.223	0.711
LS_UNICO	120	C.3	0.616	0.225	0.626	8	2.6	5	30.0	4.00	LOO	0.909	0.390	0.791


	Dataset A	Dataset B	Dataset C	Dataset UNICO
Incremento percentuale q ²	12 %	0 %	7 %	7 %



MAPPE CoMFA




Dataset	ID_Model	Probe Atom	q ² STE	q ² ELE	q ² BOTH	ONPC	Grid Spacing	Grid Extension	CutOff	Min. Sigma	CV Type	r ²	SDEC	SDEP
RDKit_A	98	F	0.567	0.445	0.642	3	2.0	10	30.0	1.00	LOO	0.929	0.281	0.630
LS_A	110	S.O	0.415	0.291	0.525	8	1.7	5	20.0	1.60	LOO	0.998	0.041	0.725




STERICHE (POS / NEG)


RDKit




ELETTROSTATICHE (POS / NEG)




LS








CONCLUSIONI



RDKit:

- Buone potenzialità per approcciarsi a metodiche di modeling farmacoforico *ligand-based*.
- Allineamenti molecolari migliori rispetto al software LigandScout.
- Modelli 3-D QSAR più stabili con valori di q^2 maggiori.





Grazie per l'attenzione!

24/01/2019